- Home
- LUCY vs SBFM Comparison
LUCY vs SBFM Comparison
Compare LUCY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- SBFM
- Stock Information
- Founded
- LUCY 2017
- SBFM 2006
- Country
- LUCY United States
- SBFM United States
- Employees
- LUCY N/A
- SBFM N/A
- Industry
- LUCY Ophthalmic Goods
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- SBFM Health Care
- Exchange
- LUCY Nasdaq
- SBFM Nasdaq
- Market Cap
- LUCY 8.9M
- SBFM 6.6M
- IPO Year
- LUCY 2022
- SBFM N/A
- Fundamental
- Price
- LUCY $2.13
- SBFM $1.54
- Analyst Decision
- LUCY
- SBFM Strong Buy
- Analyst Count
- LUCY 0
- SBFM 1
- Target Price
- LUCY N/A
- SBFM $15.00
- AVG Volume (30 Days)
- LUCY 6.0M
- SBFM 188.9K
- Earning Date
- LUCY 08-11-2025
- SBFM 08-15-2025
- Dividend Yield
- LUCY N/A
- SBFM N/A
- EPS Growth
- LUCY N/A
- SBFM N/A
- EPS
- LUCY N/A
- SBFM N/A
- Revenue
- LUCY $1,707,470.00
- SBFM $36,234,578.00
- Revenue This Year
- LUCY $367.48
- SBFM $192.48
- Revenue Next Year
- LUCY $166.67
- SBFM N/A
- P/E Ratio
- LUCY N/A
- SBFM N/A
- Revenue Growth
- LUCY 22.75
- SBFM 35.51
- 52 Week Low
- LUCY $1.57
- SBFM $1.17
- 52 Week High
- LUCY $11.16
- SBFM $7.18
- Technical
- Relative Strength Index (RSI)
- LUCY 44.28
- SBFM 51.91
- Support Level
- LUCY $2.00
- SBFM $1.43
- Resistance Level
- LUCY $2.39
- SBFM $1.61
- Average True Range (ATR)
- LUCY 0.35
- SBFM 0.11
- MACD
- LUCY -0.01
- SBFM 0.01
- Stochastic Oscillator
- LUCY 6.12
- SBFM 41.67
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.